FI971207A0 - Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen - Google Patents

Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen

Info

Publication number
FI971207A0
FI971207A0 FI971207A FI971207A FI971207A0 FI 971207 A0 FI971207 A0 FI 971207A0 FI 971207 A FI971207 A FI 971207A FI 971207 A FI971207 A FI 971207A FI 971207 A0 FI971207 A0 FI 971207A0
Authority
FI
Finland
Prior art keywords
men
pct
aromatase inhibitors
androgen deficiency
medicament
Prior art date
Application number
FI971207A
Other languages
English (en)
Swedish (sv)
Other versions
FI971207A (fi
Inventor
Albert Radlmaier
Ursula-Friederike Habenicht
Friedmund Neumann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6529877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI971207(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI971207A0 publication Critical patent/FI971207A0/fi
Publication of FI971207A publication Critical patent/FI971207A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
FI971207A 1994-09-22 1997-03-21 Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen FI971207A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4435368A DE4435368A1 (de) 1994-09-22 1994-09-22 Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
PCT/EP1995/003733 WO1996009057A1 (de) 1994-09-22 1995-09-22 Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann

Publications (2)

Publication Number Publication Date
FI971207A0 true FI971207A0 (fi) 1997-03-21
FI971207A FI971207A (fi) 1997-03-21

Family

ID=6529877

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971207A FI971207A (fi) 1994-09-22 1997-03-21 Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen

Country Status (21)

Country Link
US (1) US5861389A (fi)
EP (1) EP0782450B1 (fi)
JP (1) JPH10505848A (fi)
KR (1) KR100387345B1 (fi)
CN (1) CN1104243C (fi)
AT (1) ATE241989T1 (fi)
AU (1) AU707997B2 (fi)
BR (1) BR9509155A (fi)
CA (1) CA2200195C (fi)
CZ (1) CZ76097A3 (fi)
DE (2) DE4435368A1 (fi)
DK (1) DK0782450T3 (fi)
ES (1) ES2199255T3 (fi)
FI (1) FI971207A (fi)
HU (1) HUT76981A (fi)
MX (1) MX9702170A (fi)
NO (1) NO971349L (fi)
PL (1) PL182909B1 (fi)
PT (1) PT782450E (fi)
SK (1) SK36397A3 (fi)
WO (1) WO1996009057A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610645A1 (de) 1996-03-06 1997-09-11 Schering Ag Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6391920B1 (en) 2000-05-26 2002-05-21 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6607755B2 (en) * 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
AU2002318225B2 (en) * 2001-07-09 2007-12-13 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
CN1617715B (zh) * 2001-12-06 2010-05-12 Gtx公司 用雄激素受体选择性调节剂治疗肌消耗
US6586417B1 (en) 2002-04-22 2003-07-01 Nutrisport Pharmacal, Inc. Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans
AU2003203012A1 (en) * 2003-01-13 2004-08-13 Michael Donald Farley Improvements in or relating to anti-aromatase composition
AU2003203010A1 (en) * 2003-01-13 2004-08-13 Michael Donald Farley Improvements in or relating to anti-aromatase composition
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
US20090215906A1 (en) * 2005-02-04 2009-08-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
NZ560551A (en) * 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
KR101505884B1 (ko) * 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2
WO2009066712A1 (ja) * 2007-11-21 2009-05-28 Kracie Pharma, Ltd. アロマターゼ阻害剤
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
US20110034429A1 (en) * 2009-08-07 2011-02-10 Kneller Bruce W 5a-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
US20090306031A1 (en) * 2009-08-07 2009-12-10 Kneller Bruce W 5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) * 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
WO2013036563A1 (en) * 2011-09-08 2013-03-14 Novartis Ag Pharmaceutical compositions comprising an aromatase inhibitor
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
JP2015535283A (ja) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド 癌療法における使用のためのトランス−クロミフェン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289762A (en) * 1980-06-27 1981-09-15 Merrell Dow Pharmaceuticals Inc. 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
US4322416A (en) * 1980-06-27 1982-03-30 Merrell Dow Pharmaceuticals Inc. 10-Alkynyl steroids
EP0100566B1 (en) * 1982-07-14 1986-02-19 Akzo N.V. Novel 19-thio-androstane derivatives
DE3322285A1 (de) * 1983-06-18 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3539244A1 (de) * 1985-11-01 1987-05-07 Schering Ag 1-methyl-15(alpha)-alkyl-androsta- 1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
GB8531745D0 (en) * 1985-12-24 1986-02-05 Erba Farmitalia 10beta-alkynyl-4-9(11)-estradiene derivatives
GB8615092D0 (en) * 1986-06-20 1986-07-23 Erba Farmitalia Androst-4-ene-317-diones
DE3705990A1 (de) * 1987-02-20 1988-09-01 Schering Ag 1-methyl-15(alpha)-(1-oxyalkyl)-androsta-1,4-dien- 3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3926365A1 (de) * 1989-08-04 1991-02-07 Schering Ag Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
GB9226620D0 (en) * 1992-12-21 1993-02-17 Fujisawa Pharmaceutical Co A new compound fr 901537,production thereof and use thereof

Also Published As

Publication number Publication date
PT782450E (pt) 2003-09-30
MX9702170A (es) 1998-04-30
EP0782450B1 (de) 2003-06-04
JPH10505848A (ja) 1998-06-09
DE4435368A1 (de) 1996-03-28
AU3651895A (en) 1996-04-09
CA2200195C (en) 2008-04-22
KR100387345B1 (ko) 2003-08-30
SK36397A3 (en) 1997-08-06
BR9509155A (pt) 1997-10-14
NO971349L (no) 1997-05-16
US5861389A (en) 1999-01-19
WO1996009057A1 (de) 1996-03-28
NO971349D0 (no) 1997-03-21
DE59510714D1 (de) 2003-07-10
KR970706002A (ko) 1997-11-03
CN1158570A (zh) 1997-09-03
EP0782450A1 (de) 1997-07-09
CZ76097A3 (en) 1997-07-16
DK0782450T3 (da) 2003-08-18
ATE241989T1 (de) 2003-06-15
PL182909B1 (pl) 2002-04-30
CN1104243C (zh) 2003-04-02
PL319299A1 (en) 1997-08-04
CA2200195A1 (en) 1996-03-28
ES2199255T3 (es) 2004-02-16
AU707997B2 (en) 1999-07-29
HUT76981A (hu) 1998-01-28
FI971207A (fi) 1997-03-21

Similar Documents

Publication Publication Date Title
FI971207A0 (fi) Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen
DE60129550D1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
Miller et al. Cortisone treatment in advanced carcinoma of the prostate
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
IL114446A0 (en) New pharmaceutical preparation for pain management
DE69021214T2 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
NO964486D0 (no) Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering
BR0014312A (pt) Combinação de loteprednol e anti-histaminas
TNSN01169A1 (fr) Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.
ITRM920900A1 (it) Formulazione proteica coadiuvante nella prevenzione e cura delle parodontiti e di altre patologie batteriche del cavo orale.
Nathanson et al. The treatment of leukoplakia buccalis and related lesions with estrogenic hormone
Auletta et al. Estrogen-induced luteolysis in the rhesus monkey: reversal with indomethacin
ATE198707T1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen
DK1227814T3 (da) Hormonal sammensætning baseret på nomegestrolacetat og et östrogen samt anvendelse heraf
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
Seehusen et al. Postpartum labial adhesions
LV10839A (lv) Arstniecibas lidzeklis lipidu un holesterina vielmainas traucejumu profilaksei un arstesanai so traucejumu profilakses un arstesanas panemiens
GR3035358T3 (en) Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
HUP0303795A2 (hu) Aromatáz inhibitorok alkalmazása a fogamzás elősegítésének fokozására alkalmas gyógyszerkészítmény előállítására
Nachtigall et al. Hormone replacement therapy
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
Corcoran et al. Diagnosis and treatment of endocrine disorders in the HIV-infected patient
AP2001002167A0 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis

Legal Events

Date Code Title Description
MA Patent expired